Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Payables (2016 - 2026)

Catalyst Pharmaceuticals filings provide 17 years of Payables readings, the most recent being $7.2 million for Q1 2026.

  • On a quarterly basis, Payables fell 36.13% to $7.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $7.2 million, a 36.13% decrease, with the full-year FY2025 number at $11.2 million, down 32.49% from a year prior.
  • Payables hit $7.2 million in Q1 2026 for Catalyst Pharmaceuticals, down from $11.2 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $16.6 million in Q4 2024 to a low of $2.3 million in Q2 2022.
  • Median Payables over the past 5 years was $7.1 million (2024), compared with a mean of $7.7 million.
  • Biggest five-year swings in Payables: surged 272.2% in 2023 and later tumbled 36.13% in 2026.
  • Catalyst Pharmaceuticals' Payables stood at $4.0 million in 2022, then surged by 272.2% to $14.8 million in 2023, then grew by 12.15% to $16.6 million in 2024, then tumbled by 32.49% to $11.2 million in 2025, then plummeted by 36.16% to $7.2 million in 2026.
  • The last three reported values for Payables were $7.2 million (Q1 2026), $11.2 million (Q4 2025), and $9.1 million (Q3 2025) per Business Quant data.